ZyVersa Therapeutics (ZVSA) Stock Chart & Stock Price History $0.14 -0.01 (-5.71%) As of 08/22/2025 03:17 PM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZyVersa Therapeutics Stock Price Performance The ZyVersa Therapeutics (ZVSA) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 95.32%, with a year-to-date return of -86.92%. In the past month, the stock has decreased 42.25%, reflecting recent market activity. As of the latest close, ZyVersa Therapeutics traded at $0.14 with a market cap of $1.10 million and volume of 40,940 shares. Receive ZVSA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-7.60%1 Month Performance-42.25%3 Month Performance-74.33%Year-To-Date Performance-86.92%1 Year Performance-95.32% ZVSA Stock Chart for Sunday, August, 24, 2025 ZVSA Chart by TradingView ZyVersa Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$0.15$0.14-5.71%$0.15$0.1140,940 shs$1.10 million08/21/2025$0.14$0.15+2.15%$0.15$0.11123,864 shs$1.17 million08/20/2025$0.15$0.14-4.07%$0.15$0.1436,703 shs$1.19 million08/19/2025$0.15$0.15$0.16$0.1358,415 shs$1.19 million08/18/2025$0.15$0.15-2.85%$0.16$0.1537,985 shs$1.19 million08/15/2025$0.15$0.15+2.39%$0.16$0.12147,854 shs$1.23 million08/14/2025$0.15$0.15+0.40%$0.17$0.1423,572 shs$1.20 million08/13/2025$0.14$0.15+6.90%$0.16$0.1425,899 shs$732,000.0008/12/2025$0.14$0.14+0.14%$0.17$0.1427,738 shs$685,000.0008/11/2025$0.17$0.14-17.47%$0.16$0.1332,321 shs$684,000.00 Get the Latest News and Ratings for ZVSA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$0.17$0.17-0.06%$0.18$0.1367,838 shs$828,000.0008/07/2025$0.16$0.17+9.74%$0.18$0.15129,122 shs$829,000.0008/06/2025$0.16$0.16-5.55%$0.17$0.1641,721 shs$755,000.0008/05/2025$0.18$0.16-8.93%$0.18$0.1621,255 shs$800,000.0008/04/2025$0.19$0.18-2.75%$0.22$0.1829,292 shs$878,000.0008/01/2025$0.20$0.19-6.84%$0.23$0.1819,573 shs$902,000.0007/31/2025$0.20$0.20-0.55%$0.23$0.1843,948 shs$969,000.0007/30/2025$0.25$0.20-20.57%$0.25$0.1977,419 shs$974,000.0007/29/2025$0.26$0.25-1.25%$0.27$0.2364,062 shs$1.23 million07/28/2025$0.27$0.26-5.56%$0.28$0.22359,873 shs$1.24 million07/25/2025$0.24$0.27+12.50%$0.28$0.24111,662 shs$1.32 million07/24/2025$0.24$0.24+2.13%$0.29$0.22522,706 shs$1.17 million07/23/2025$0.15$0.24+59.32%$0.25$0.15622,469 shs$1.15 million Related Companies VIVS Stock Price Chart TTNP Stock Price Chart CPHI Stock Price Chart PALI Stock Price Chart PWUP Stock Price Chart INM Stock Price Chart GLTO Stock Price Chart CDT Stock Price Chart GTBP Stock Price Chart BDRX Stock Price Chart Receive ZVSA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ZVSA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access